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1 Abstract 20 
1.1 BACKGROUND:  21 
2 
 
The early life period represents the first step in establishing a beneficial microbial 22 
ecosystem, which in turn affects both short and longer-term health. Changes during 23 
pregnancy influence the neonatal microbiome; through transmission of maternal 24 
microbes during childbirth, and beyond, through nutritional programming. However, in-25 
depth exploration of longitudinal maternal-infant cohorts, with sampling of multiple body 26 
sites, complemented by clinical and nutritional metadata, and use of cutting-edge 27 
experimental systems are limited. 28 
The PEARL study will increase our knowledge of; how microbes (including 29 
viruses/phages, bacteria, fungi and archaea) change in composition and functional 30 
capacity during pregnancy; transmission pathways from mother to infant; the impact of 31 
various factors on microbial communities across pregnancy and early life (e.g. diet), and 32 
how these microbes interact with other microbes and modulate host processes, including 33 
links to disease onset. 34 
1.2 METHODS:  35 
PEARL is a longitudinal observational prospective study of 250 pregnant women and 36 
their newborns, with stool and blood samples, questionnaires and routine clinical data 37 
collected during pregnancy, labour, birth and up to 24 months post birth.  38 
Metagenomic sequencing of samples will be used to define microbiome profiles, and 39 
allow for genus, species and strain-level taxonomic identification and corresponding 40 
functional analysis. A subset of samples will be analysed for host (immune/metabolite) 41 
molecules to identify factors that alter the host gut environment. Culturing will be used to 42 
identify new strains of health-promoting bacteria, and potential pathogens. Various in 43 
vitro and in vivo experiments will probe underlying mechanisms governing microbe-44 
microbe and microbe-host interactions.  45 
1.3 DISCUSSION: 46 
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Longitudinal studies, like PEARL, are critical if we are to define biomarkers, determine 47 
mechanisms underlying microbiome profiles in health and disease, and develop new 48 
diet- and microbe-based therapies to be tested in future studies and clinical trials.  49 
1.4 TRIAL REGISTRATION: 50 
This study is registered in the ClinicalTrials.gov Database with ID: NCT03916874 51 
1.5 KEYWORDS: 52 
Microbiome, Pregnancy, Early-life, Gut health, Health 53 
2 Background 54 
The human gut microbiota comprises a complex microbial ecosystem (including 55 
viruses/phages, bacteria, fungi and archaea) which benefit their host through acquisition of 56 
additional nutrients and energy from dietary components, optimised development of the 57 
immune system, and resistance against pathogens [1,2].  As the neonatal gut is essentially 58 
sterile, these beneficial microbes and their associated functions, must be acquired during 59 
and after birth; this is achieved through initial colonisation by pioneer bacteria, successive 60 
diversification, and changes in microbial population densities over time, until a climax or 61 
‘stable’ microbiome is established during infancy and early childhood [3,4]. 62 
The initial colonisation and establishment of the gut microbiome during early life influences 63 
physiological and immune development [4]. Critically, disturbances within this pioneering 64 
microbial community (both in mother and infant) have the potential to increase the risk of 65 
developing diseases such as autoimmune conditions, allergic-type disorders, infections and 66 
chronic intestinal diseases [4,5,6]. Factors such as antibiotic usage, diet (i.e. breast versus 67 
formula milk) and birth mode (i.e. Caesarean section versus vaginal) can affect the gut 68 
microbiota during this time [7,8,9].  69 
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Transmission of microbial species from the maternal microbiome to the infant occurs at birth, 70 
with subsequent waves of colonisation occurring as the infant ages [10,11,12]. There is also 71 
an increasing awareness of the importance of maternal health during pregnancy for infant 72 
development and health, both before and after birth [13]. Importantly, these life stage events 73 
appear to be governed by particular interactions (immune and dietary) that ‘select’ beneficial 74 
microbes such as Bifidobacterium [4,14,15]. Species in this genus are prevalent in the 75 
gastrointestinal tract of mothers in the later stages of pregnancy and can represent up to 76 
80% of the total microbiome in healthy infants [14,16,17]. These pioneering microbial 77 
species and strains contribute to ecosystem structuring, which is heavily influenced by their 78 
ability to metabolise complex sugars presents in breast milk – human milk oligosaccharides 79 
[17].  80 
Although several studies have looked at these key factors at these critical timepoints, there 81 
are still many unknowns with respect to this key developmental window including; how the 82 
microbiome changes in response to different phases of pregnancy across different body 83 
sites; whether microbes from mothers are directly passed to infants during birth, and how 84 
birth mode affects this (i.e. vaginal birth vs. C-section); how factors like diet and antibiotics 85 
influence the maternal microbiome, and what impact this has on developing infant microbial 86 
communities; how different feeding regiments (e.g. breast vs. formula milk) influence specific 87 
microbial populations in the infant (e.g. Bifidobacterium); how these microbes influence 88 
immune and metabolic health.; and if in-depth mechanistic studies using in vitro and in vivo 89 
models can determine how specific microbes and communities contribute to healthy 90 
development and prevent disease incidence. 91 
 Longitudinal pregnancy and infant studies like PEARL, will provide an invaluable resource to 92 
study the importance of the early life microbiome. Gathering these data is critical for 93 
identification and development of new therapies and health- associated practices to improve 94 
health, both in the short- term and across the life course. 95 
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2.1 OBJECTIVES:  96 
The primary objective of the PEARL study is to describe the determinants, function and 97 
composition of maternal and neonatal microbiomes throughout pregnancy and early 98 
childhood in a cohort of mothers and babies without serious health conditions. 99 
Other objectives of this study are; 100 
1) to link or correlate microbiome profiles to routinely collected clinical information in 101 
mothers and infants (e.g. antibiotic usage, birth mode) and dietary information via 102 
questionnaires (e.g. breast vs. formula milk), and to host metabolites and immune 103 
markers (e.g. cytokines) measured in samples collected; 104 
2) to use microbiome samples in preclinical models to describe the role that the 105 
early- life microbiome plays in immune and metabolic development and resistance to 106 
diseases;  107 
3) to use analysis and microbiome samples (using in vitro and preclinical models) to 108 
characterise the cause, effect and consequences of disturbances in the early-life 109 
microbiome due to external factors (e.g. antibiotics, birthing method, diet) on 110 
subsequent health outcomes; 111 
4) to define and characterise early-life associated microbiome species (e.g. 112 
Bifidobacterium species and Enterococcus species) from samples for their 113 
probiotic/pathogenic traits (using in vitro and preclinical models). 114 
An additional key output, which will be available to the wider research community, is a 115 
comprehensive collection of microbiome samples and associated clinical and diet/lifestyle 116 
information that will be accessible via requests to Professor Lindsay Hall and the Norwich 117 
Research Park (NRP) Biorepository, with all microbiome sequence data publicly available 118 
after deposition in public repositories. 119 
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3 METHODS: 120 
PEARL is a longitudinal study of 250 pregnant women and their new born(s). Biological 121 
samples and data will be collected in pregnancy, labour, birth and up to 24 months post 122 
birth. In the event of multiple live births, each infant will be included. Figure 2 provides an 123 
overview of the overall design of the study and shows which samples and data are collected 124 
at each timepoint. There are up to 12 collection timepoints, as well as 4 optional blood 125 
sample donations which will be collected at routine maternity care appointments. The study 126 
is divided into three collection phases: pregnancy, birth to four months, and four months to 127 
24 months post birth. 128 
Pregnant women can be recruited to PEARL at any time up to 22 weeks gestation.  During 129 
phase 1 participants will be asked to collect samples and complete questionnaires during 130 
each of the three trimesters of pregnancy if they are involved in the study at that point. 131 
Participants are also able to donate blood samples at weeks 12, 16, 20, 28. 132 
During phase 2, participants will collect samples at three timepoints from themselves and 133 
their infant(s); birth, at 1 week post birth, and at 3 weeks post birth.  134 
Phase 3 collections will be every 4 months (4, 8, 12, 16, 20 and 24 months). With the 135 
exception of month 4, further collections of samples will be from the infant only.  136 
At each collection time point, there is a window of 7 days within which the participant can 137 
collect their samples. This is to provide as much flexibility for participants as possible. 138 
Participants will receive a reminder message via text message or email when their samples 139 
are due to be taken, and again towards the end of the timepoint window.  140 
Most samples will be collected at home using packs provided to the participants. The 141 
participants will be provided with a small freezer where they will store their samples until 142 
collected by a member of the research team. This freezer will be dedicated to holding study 143 
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samples to minimize any cross-contamination risks to the participant. Collections from the 144 
participants’ homes will occur at 4 points throughout the study after phase 1, after phase two 145 
and at month 12 and month 24 during phase 3.  146 
At birth, or any time the participant or her infant is an inpatient at the Norfolk and Norwich 147 
University Hospitals NHS Foundation Trust (NNUH), participants can collect their samples at 148 
the NNUH and give them to their midwife/obstetrician who will put these in the PEARL study 149 
freezer located at the hospital.  150 
The sample collection protocol has been designed using significant optimisation information 151 
from our previous study, BAMBI [18], with additional information gathered from other 152 
longitudinal cohort studies including the Flemish Gut Project [19], and we are confident that 153 
our current protocol will allow participants to easily collect and store samples at -20◦C until 154 
collection.  155 
After collection from participants’ homes, all samples will be appropriately aliquoted and will 156 
be stored in QIB at -80°C prior to analysis. Additional aliquots may also be stored at the 157 
NRP Biorepository at -80°C for future research if the participant has provided this additional 158 
consent.  159 
Participants will complete 3 questionnaires during the study (timepoints detailed in figure 2) 160 
including questions on health, lifestyle, and diet. The questionnaires include: 161 
• Centre for Disease Control and Prevention (CDCP) questionnaires for pregnancy, 162 
breastfeeding and infant feeding practices [20]. Modified, with permission, for the 163 
purposes of this study (supplementary files 1 - 7). 164 
• A health questionnaire to provide information on lifestyle, diet and 165 
medication/medical history, developed for the study (supplementary files 8-9). 166 
• A dietary perceptions and preferences questionnaire, developed for the study 167 
(supplementary files 10-12). 168 
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The research team will also collect; clinical information from GP and hospital records that 169 
relate to any change in the participants or her infants' medical history during the course of 170 
the study; routine data collected by health visitors (developmental Ages & Stages data) 171 
which includes information on fine and gross motor skills and problem solving; and routine 172 
pregnancy scans and tests. 173 
COVID19 Mitigation Strategies 174 
In response to the COVID-19 pandemic, it is important to implement a risk mitigation 175 
strategy to protect the health and safety of both participants and researchers. Participants 176 
will be advised that they should not collect samples if they or anyone in their household has 177 
COVID19 symptoms, are self-isolating, are awaiting test results, or have in the last 70 days 178 
tested positive for COVID19. The research team will send collection packs and arrange the 179 
collection of participants’ samples following Standard Operating Procedures (SOPs)/ 180 
COVID-19 risk-assessments. 181 
3.1 PARTICIPANT SELECTION 182 
3.1.1 Sample Size 183 
PEARL will recruit 250 pregnant women.  Our primary aim is to detect associations between 184 
aspects of neonatal and maternal microbiomes, and their associations with external factors. 185 
As an indicative power calculation, if a potential risk factor has a prevalence of 25% (recent 186 
data suggests that 25% of mothers who deliver at our recruitment hospital [Norfolk and 187 
Norwich University Hospitals NHS Foundation Trust – NNUH] do not initiate breast feeding; 188 
the UK Caesarean section rate is also currently around 25%). Then with 200 observations 189 
we would have power of 80% to detect a difference of 0.46 standard deviations in any given 190 
outcome measure between those with and without the feature at a p-value of 0.05. This is 191 
commonly understood to correspond to a ‘moderate’ size of effect between an exposure and 192 
an outcome. 193 
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For continuous outcomes or correlations between 250 mother and baby pairs, we would be 194 
able to detect correlations of r=0.2 with 80% at p<0.05. This corresponds to a continuous 195 
feature accounting for r2=4% of the population variation in any given characteristic of the 196 
microbiome. 197 
For secondary analyses, if the p-value threshold for statistical significance is corrected to 198 
p<0.005 to account for multiplicity then the corresponding smallest detectable differences 199 
are 0.6 standard deviations between groups defined by a binary factor (e.g. mode of delivery 200 
or breastfeeding) or correlation of 0.25 between continuous variables. 201 
Previously, Azad et al (2015) [21] explore effects of maternal antibiotic use, mode of delivery 202 
and breastfeeding on diversity and major taxon abundance among a cohort of 198 Canadian 203 
neonates at 3 and 12 months of age. Differences in the three most abundant taxa between 204 
elective Caesarean section (n=19) and vaginal births (n=96) were detected at three months 205 
with p-values of <0.001 and <0.01, corresponding to effect sizes of >0.63 and >0.49 206 
standard deviations. 207 
3.1.2 Cohort 208 
250 healthy pregnant women will be recruited from across Norfolk. We will be recruiting 209 
participants from the maternity unit at a single major regional hospital, the Norwich and 210 
Norfolk University Hospital Foundation Trust (NNUH) which provides care for a population of 211 
approximately 1,000,000. The vast majority of women in the region will use the maternity 212 
services of this hospital. Participants will all be planning to give birth at NNUH or have a 213 
home birth with their maternity care provided by the NNUH. The total number of live births 214 
per year at NNUH is ~6000. Our primary objective is to describe the determinants, function 215 
and composition of maternal and neonatal microbiomes throughout pregnancy and early 216 
childhood in a cohort of mothers and their babies without serious health conditions. 217 
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Therefore, we will be seeking a ‘healthy’ cohort of mothers, with the following inclusion and 218 
exclusion criteria applied. 219 
Inclusion criteria 220 
• Confirmed pregnancy and aged at least 18 years. 221 
• Must be able to understand the requirements of the study and provide signed and 222 
dated informed consent for herself and her unborn child. 223 
• Planning to give birth at NNUH or at home under the care of NNUH. 224 
• At the point of study consent, be ≤22 weeks pregnant. 225 
• Body Mass Index (BMI) between 18 and 35kg/m2 226 
• Must be willing to provide biological samples over a period of 31 months (urine 227 
samples, stool samples, low vaginal swabs, skin swabs and breast milk (if 228 
breastfeeding this is optional). Blood samples are optional. 229 
• Must be willing to accommodate a small freezer to store frozen samples for the 230 
duration of the study. 231 
• Must be willing to complete study questionnaires over a period of 31 months. 232 
Exclusion criteria 233 
The participant may not enter the study if ANY of the following apply: 234 
• Pregnancy is for surrogacy purposes. 235 
• Planned adoption, fostering of baby or baby not planned to be living with 236 
biological mother. 237 
• Currently taking part in an interventional study. 238 
• Living with or related to a member of the research team. 239 
• Current smoker. 240 
• Taken antibiotics or antifungals or antivirals within the last 3 months. 241 
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• Taken steroids within the last 6 months. 242 
• Currently taking more than a daily dose of probiotics. 243 
• History of polyps within the gut. 244 
• Long-standing gastrointestinal or liver function abnormality requiring on-going 245 
medical management or medication. 246 
• Current or history of cancer except for squamous or basal cell carcinomas of the 247 
skin that have been medically managed by local excision. 248 
• Unstable dietary history as defined by major changes in diet during the previous 249 
month, where the participant has stopped or significantly increased a major food 250 
group in the diet, for example changed to vegan, vegetarian or stopped eating 251 
red meat. 252 
• History of alcohol, drug or substance abuse. 253 
• History of Hepatitis B or Hepatitis C. 254 
• Any confirmed or suspected pre-existing condition/state of immunosuppression or 255 
immunodeficiency (primary or acquired), for example Rheumatoid Arthritis, Type 256 
1 Diabetes, Multiple Sclerosis, Asthma, Eczema and Psoriasis. (Participants who 257 
are asymptomatic of Asthma, Eczema and Psoriasis in the last 5 years can be 258 
included in the study). 259 
• Major surgery of the gastrointestinal tract, apart from gall bladder or appendix 260 
removal, in the past five years. 261 
• Any major bowel resection at any time. 262 
• History of Ulcerative Colitis or Crohn's Disease or Diverticulitis. 263 
• Persistent, infectious gastroenteritis, gastritis, persistent or chronic diarrhoea of 264 
unknown cause, Clostridium difficile infection (recurrent) or Helicobacter pylori 265 
infection (untreated). 266 
• Chronic constipation. 267 
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3.2 RECRUITMENT 268 
Recruitment began in May 2019 and will continue until May 2022. Recruitment will be mainly 269 
opportunistic at the NNUH NHS Foundation Trust antenatal clinics and midwife led 270 
community clinics in GP surgeries and health clinics.  271 
In response to the COVID19 pandemic, digital appointments have been put in place for 272 
pregnant women that replace the community clinics in GP surgeries and health clinics.  Due 273 
to the efficiencies that this brings, it is anticipated that these appointments will remain 274 
common practise even after measures put in place to control the pandemic have been lifted. 275 
We, therefore, also intend to include virtual recruitment as a routine recruitment method for 276 
this study.  277 
Following the first appointment a pregnant woman has as part of her routine maternity care 278 
at NNUH, eligible, patients considered to have a low risk pregnancy will be contacted by a 279 
research midwife by telephone to introduce the study and ask if the participant is interested 280 
in taking part. If the participant is interested, they will be provided with the participant 281 
information sheet (PIS) via email and a video/telephone call will be arranged to continue the 282 
informed consent process if they so wish. Participants may also contact the study researcher 283 
directly by entering their interest into the expression of interest form on the PEARL study 284 
web page, by telephone, or via email. Participants may request a face to face consent 285 
appointment which will be held at the Quadram Institute Clinical Research Facility, however, 286 
this may not be possible if there are local restrictions in place to manage the COVID19 287 
pandemic. Written informed consent will be obtained following Good Clinical Practice (GCP) 288 
guidelines by the research midwife or a member of the research study team.  289 
The participant will then be assigned their unique PEARL study participant number which will 290 
provide pseudonymisation for the participant throughout the study.  291 
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It will be clearly stated that the participant is free to withdraw from the study at any time for 292 
any reason without prejudice to future care, without affecting their legal rights, and with no 293 
obligation to give the reason for withdrawal. 294 
3.3 SAMPLE BANKING AT THE NRP BIOREPOSITORY 295 
A key aspect of the PEARL study involves creating biobank of samples and data which 296 
can be used in future ethically approved research. To enable this, and following 297 
Informed Consent for study participation, all participants will be asked if they would be 298 
willing for their samples to be stored anonymously at the Norwich Research Park (NRP) 299 
Biorepository during and after the end of the study for long term storage. The NRP 300 
Biorepository is a tissue bank licensed by the UK’s Human Tissue Authority (HTA) with 301 
appropriate ethics approval which was granted by the NHS Health Research Authority 302 
(HRA), East of England-Cambridge East Research Ethics Committee (REC).  Samples 303 
stored at NRP Biorepository will be used in future ethically approved research. 304 
Participants consenting to the long-term storage of their samples at the NRP 305 
Biorepository are given the option to provide explicit consent for their samples to 306 
potentially be used in future ethically approved animal, cloning, or commercial studies, 307 
however, these aspects are optional and not required for samples to be stored long term 308 
in the NRP Biorepository. Data will be recorded by returning a copy of the consent form 309 
to the Biorepository. The participant will be asked to read the current version of the NRP 310 
Biorepository Information Sheet and to sign this consent if they wish to participate in this 311 
aspect of the study. If the participant declines long term storage at the NRP 312 
Biorepository, all samples at the end of the study will be destroyed appropriately in 313 
accordance with the Human Tissue Act requirements. 314 
3.4 STATISTICS AND ANALYSIS 315 
3.4.1 Interim Analyses 316 
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Interim reports will include the number of accruals to the study, the quality of the samples 317 
returned, the completeness and validity of the questionnaire data returned. The report will 318 
also detail any missing data and any participants who are lost to follow-up. 319 
3.4.2 Analysis of Samples 320 
Samples will be subjected to microbiome analysis using high-throughput sequencing 321 
following standardised protocols validated and quality controlled from BAMBI SOPs, 322 
including: shotgun metagenomics for species-level taxonomic identification; functional 323 
profiling; and analysis of the gut-associated antimicrobial resistance ‘resistome’ using open 324 
access bioinformatics pipelines and new pipelines. 325 
Bioinformatics pipelines are constantly being improved/updated, thus we will use the most 326 
appropriate ones available at time of analysis which may include e.g. MetaPhlAn 3 [22]. 327 
Downstream statistical analyses will also be performed by using various packages in R. 328 
Stool samples will also be analysed for host (immune/metabolite) molecules to determine 329 
which factors (e.g. antibiotics, diet) alter the host gut environment, which will be carried out  330 
using standard lab protocols (e.g. multi-plex cytokine assays, and NMR metabolomics). 331 
Samples will also be cultured (single and complex [i.e. model colon systems]) to identify new 332 
strains of beneficial or ‘probiotic’ bacteria such as Bifidobacterium species, and also any 333 
potential pathogens, for use in additional in vitro and in vivo studies to answer specific 334 
questions about how early life microbes modulate host functions. 335 
3.5 DESCRIPTION OF STATISTICAL METHODS 336 
A main aim of this study is to establish a cohort and repository of samples for future 337 
research, hence there are many possible future analyses that may be done using the 338 
samples collected as a part of this study. 339 
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For primary analyses, the composition of the microbiome in each sample (as defined by 340 
participant, site and time point) will be described in terms of individual taxon abundance and 341 
overall measures of diversity. Several key aspects of composition of the maternal and 342 
neonatal microbiome will be identified as candidates for association with measures of health 343 
status based on review of previous studies and theoretical considerations. 344 
The dynamics of microbiome development and transmission from mother to baby will be 345 
determined by describing and correlating the distribution of key measures of structure and 346 
composition between samples. 347 
The effect of factors that might affect microbiome composition, such as breastfeeding 348 
initiation and mode of delivery, will be assessed using regression models. 349 
For exploratory (hypothesis generating) analyses, multivariate methods such as partial least 350 
squares regression modelling will be used to explore internal correlation structure within 351 
each sample and test whether any set of microbiome characteristics identified correlates 352 
with a hypothesised clinical factor. 353 
Throughout, careful attention will be paid to the possibility of false positive results occurring 354 
through multiplicity given the large number of hypotheses being tested and the large number 355 
of parameters to be set in bioinformatics and statistical techniques. This will be mitigated as 356 
far as possible for each hypothesis by clearly pre-specifying each individual analysis in a 357 
statistical analysis plan detailing the coding of exposures, outcomes and covariates and 358 
primary statistical methods to be employed including any subgroup analyses. These 359 
statistical analysis plans will be developed and will be pre-registered following data collection 360 
so that the distributions of key variables are known but before relevant analysis of 361 
microbiome and health outcome information is undertaken. Exploratory and secondary 362 
analyses will be clearly reported as such in all outputs, and results from all analyses will be 363 
published irrespective of whether findings are predominantly positive or negative. 364 
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3.6 STUDY MANAGEMENT PLAN 365 
3.6.1 Trial Management Group  366 
The Trial Management Group including the Chief Investigator (Prof Lindsay Hall), the study 367 
research team, NHS Principal Investigators and Clinical Research Network’s (CRN) 368 
Research Nurses will be responsible for the day-to-day management of the trial. They will 369 
monitor all aspects of the conduct and progress of the trial, ensure that the protocol is 370 
adhered to and take appropriate action to safeguard participants and the quality of the trial 371 
itself.  372 
3.6.2 Trial Management Oversight Group 373 
Management of the study will be overseen by a Trial Management Oversight Group whose 374 
membership is made up of representatives from;  375 
• Health, Safety, Environment and Quality Assurance.  376 
• QIB Sponsor Representative.  377 
• Gut Microbes and Health QIB Programme Manager.  378 
• QIB Statistician.  379 
• Information Technology Security Specialist.  380 
• NRP Biorepository.  381 
• Patient and Public Involvement.  382 
• QIB Bioinformatician.  383 
 384 
The Trial Management Oversight Group will be responsible for overseeing the running of the 385 
study. They will ensure the monitoring and facilitating the progress of the study, and ensure 386 
the study is delivered within the projected timelines. Recruitment targets, success of data 387 
collection, and any specific issues arising will be addressed. 388 
3.7 DATA MANAGEMENT PLAN 389 
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3.7.1  Description of the Data 390 
Our data collected for this study will be the following: - 391 
• Clinical data and measurements taken as part of routine care (Antenatal and Postnatal 392 
Data Collection Case Report Forms). 393 
• Participant-reported general health and lifestyle data (Participant Trimester 2 and 394 
Participant 24 months Post Birth Health Questionnaires – Supplementary files 8 and 9) and 395 
Participant Dietary Preferences and Perceptions Questionnaire (Participant Trimester 2, 4 396 
months post birth and 24 months post birth – supplementary files 10 - 12). 397 
• CDCP questionnaires, (participant-reported data, dietary intake and allergies data – 398 
supplementary files 1 - 7). 399 
• Biological Sample data (blood, stool, urine, colostrum/breast milk, cord blood, low vaginal 400 
swabs, skin swabs and meconium samples). 401 
• Data collected from NNUH Integrated Clinical Environment (ICE) system (routine 402 
pregnancy results), other relevant databases within the Trust and hospital notes where it is 403 
relevant to the study. 404 
All of the above collected data will be anonymised and stored on a secure IT (Information 405 
Technology) system which only the study research team will have access to. 406 
A data monitoring committee is not needed because the trial is not testing a drug or device 407 
and any safety concerns associated with the trial have been reviewed by the ethics 408 
committee. 409 
3.7.2 Specific Management of Samples 410 
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All biological samples and data collected as part of the study will be pseudonymised. 411 
Laboratory results will be maintained in a database and will be in file formats that can be 412 
shared internally. Sample management at QIB and the NRP biorepository will be enabled by 413 
use of a locally acquired Laboratory Information Management System. Only anonymised 414 
individual-level data will be shared within study team members (QIB and NHS investigators). 415 
3.7.3 Data Collection / Generation 416 
Data from medical records (hospital notes and GP records) will be extracted onto study-417 
specific, ethically approved, forms and then uploaded into secure databases which has 418 
shared access with appropriately authorised research staff working on the project in 419 
compliance with International Good Clinical Practice (GCP) standards. 420 
3.7.4 Data Sharing and Access 421 
The research protocol is registered at ClinicalTrials.gov (NCT03916874).  The study team 422 
will ensure full compliance with the standards required for deposition of information in any 423 
relevant public databases. Only anonymised individual-level datasets will be shared outside 424 
the team. Consent forms clearly state the data sharing procedures for data generated from 425 
this study. 426 
All data will be managed, protected and shared in accordance with the requirements the 427 
Biotechnology and Biological Sciences Research Council (BBSRC) Data Sharing Policy. 428 
Direct access will be granted to authorised representatives from the Sponsor and host 429 
institution for monitoring and/or audit of the study to ensure compliance with regulations. 430 
ETHICAL AND REGULATORY CONSIDERATIONS 431 
3.7.5 Declaration of Helsinki and Relevant Regulations 432 
The Investigator will ensure that this study is conducted in accordance with the principles of 433 
the Declaration of Helsinki. The proposed research will be conducted in accordance with the 434 
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conditions and principles of the International Conference on Harmonisation Good Clinical 435 
Practice, and in compliance with national law. The research will meet the requirements of the 436 
new EU General Data Protection Regulation (GDPR), UK Data Protection Act 2018 and 437 
relevant sponsor’s policies. 438 
3.7.6 Expenses and Benefits 439 
There are no planned in-person study visits for this study. However, if a participant requests 440 
a face to face consent appointment at the Quadram Institute Clinical Research Facility, 441 
provisions will be made to reimburse the participant for car parking, and travel expenses at 442 
45p per mile. As a thank you, participants will be sent a £20 shopping voucher once the 24-443 
month samples and data have been received. At the end of the study, the participant will 444 
also have the option of keeping the freezer if they wish. 445 
It is not anticipated that any post-trial care will be required. If any participant is harmed 446 
whilst taking part in this clinical research study as a result of negligence on the part of a 447 
member of the study team, QIB holds liability insurance for such circumstances. 448 
4 Discussion 449 
Only by conducting in-depth longitudinal studies of large cohorts of hosts (i.e. mothers and 450 
their babies in the case of PEARL) can we identify the factors that are responsible for 451 
shaping and sustaining the microbiome in health, or for causing disturbances in disease.  452 
Longitudinal studies, like PEARL, are critical if we are to define biomarkers and develop new 453 
diet- and microbe-based therapies to promote health during pregnancy and early life in 454 
future studies and clinical trials [23]. Our pregnant mother and baby cohort will provide a 455 
unique collection of samples robustly linked to detailed clinical information and early-life diet 456 
information, which will be available to the wider research community, thus providing a 457 
significant UK-based resource. 458 
A significantly novel aspect of PEARL, is to input clinical samples and data into experimental 459 
model systems to show how the microbiome modulates specific early life developmental 460 
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programming, and to ‘collect’ novel early life associated microbiome species (e.g. 461 
Bifidobacterium, Ruminococcus, Enterococcus) that can be used in these systems, and why 462 
may form the basis of for future microbiota modulation clinical trials. 463 
Our protocol for PEARL from the first trimester of pregnancy and foetal development through 464 
to early childhood has been designed to complement other UK-based cohort studies looking 465 
at pregnancy and early life such as the BabyBiome Study [24] and COCO90s [25]. However, 466 
to the best of our knowledge, no study has attempted to undertake a comprehensive 467 
microbiome analysis throughout pregnancy and into infanthood, and none have linked this to 468 
detailed patient information that we are gathering through routine clinical data collection, 469 
lifestyle, and dietary information. 470 
The major unanticipated operational issue impacting the PEARL study during 2020-2021 is 471 
the COVID-19 pandemic. With this, came implementation of national and local restrictions to 472 
reduce transmission of the virus. This included stay at home orders, social distancing and 473 
requirements to work from home where possible. The impacts on research studies such as 474 
PEARL have been significant.  475 
Early in the pandemic, the PEARL study had to temporarily pause research activities while 476 
risk assessments could be urgently revised and adaptions to processes could be established 477 
to ensure safety of both participants and staff. We developed a remote process to recruit 478 
participants and introduced a reduced collection schedule from participants’ homes to 479 
reduce any face to face contact involved in taking part in the study. All sample collections 480 
adhere to local and national guidelines on COVID-19 restrictions set out by the government. 481 
During a second wave of the pandemic and increased pressure on local NHS trusts, we had 482 
to temporarily pause all recruitment activity to release any NHS resource that we were using 483 
for recruitment activities. 484 
21 
 
We have seen an increased withdrawal rate to the study at times when local restrictions for 485 
COVID-19 have been implemented which could be attributed to the increased stress brought 486 
on by these ‘locked down’ environments, such as increased workload of working families to 487 
home school children. Therefore, not wishing to continue in the research environment. 488 
We have made several amendments to the study to increase safety of participants and 489 
research staff during the pandemic, with the hope that these actions will mean the PEARL 490 
study will not be affected in the long term.  491 
It is likely COVID-19 will have implications on future studies and risk assessments should be 492 
made prior to set up.  493 
5 List of abbreviations 494 
BAMBI study - Baby-Associated MicroBiota of the Intestine study 495 
BBSRC - Biotechnology and Biological Sciences Research Council 496 
BMI - body mass index 497 
CDCP – Centre for Disease Control and Prevention 498 
CI – chief investigator 499 
CRN – Clinical Research Network 500 
GCP - Good Clinical Practice (GCP)  501 
GDPR - General Data Protection Regulation 502 
GP – General Practitioner 503 
HRA – Health Research Authority  504 
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HRGC – Human Research and Governance Committee 505 
ICH GCP - International Conference on Harmonisation Good Clinical Practice 506 
ICE – Integrated Clinical Environment  507 
IT – Information Technology 508 
NHS – National Health Service 509 
NIHR – National Institute for Health Research 510 
NNUH – Norfolk and Norwich University Hospitals NHS Foundation Trust 511 
NRP – Norwich Research Park 512 
PIS – Participant Information Sheet 513 
QI CRF – Quadram Institute Clinical Research Facility 514 
REC – Research Ethics Committee 515 
SOPs - standard operating procedures 516 
6 Declarations 517 
6.1 ETHICS APPROVAL AND CONSENT TO PARTICIPATE 518 
The PEARL study has been reviewed and agreed by the Human Research Governance 519 
Committee at the Quadram Institute Bioscience and the London-Dulwich Research Ethics 520 
Committee (reference 18/LO/1703) and received written ethical approval by the Human 521 
Research Authority. IRAS project ID number 241880. 522 
All participants in the PEARL study must be able to understand the requirements of the 523 
study and provide signed and dated informed consent for themselves and their unborn child. 524 
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An annual progress report will be submitted to the REC committee, HRA (and sponsor). In 525 
addition, an end of study notification and final report will be submitted to the same parties. 526 
All amendments to the study protocol will be submitted to the London-Dulwich Research 527 
Ethics Committee for their approval and are reported to the sponsor and investigators. 528 
Solicited and spontaneously reported adverse events and other unintended effects of the 529 
trial interventions and trial conduct will be recorded regularly in line with ethics 530 
requirements. The sponsor may conduct random audit processes to ensure compliance to 531 
the current protocol. 532 
6.2 CONSENT FOR PUBLICATION 533 
Not Applicable 534 
6.3 AVAILABILITY OF DATA AND MATERIALS 535 
Data generated from the PEARL study will adhere to the Biotechnology and Biological 536 
Sciences Research Council (BBSRC) Data Sharing Policy. Anonymised datasets will be 537 
kept indefinitely and available to other researchers. Access to such data should be 538 
requested through the Chief Investigator, Professor Lindsay Hall. 539 
There will be no limitations to the dissemination of the results. It is anticipated that the 540 
results of this research project will be published and/or presented in a variety of forums, 541 
including peer reviewed journal publications, conference presentations, communications 542 
and media releases. In any publication and/or presentation, information will be provided 543 
in such a way that participants cannot be identified. 544 
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constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356. The study is into the 550 
NIHR CRN Central Portfolio Management System (CPMS, add study number and speciality) 551 
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support. George Savva is funded through the BBSRC Core Capability Grant BB/CCG1860/1 553 
at the Quadram Institute Bioscience. The Achiever Medical Laboratory Information 554 
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study design; data collection, management, analysis and interpretation; and writing of 558 
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